Grandfield & Dodd LLC Takes $1.04 Million Position in BioMarin Pharmaceutical Inc. $BMRN

Grandfield & Dodd LLC acquired a new position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 18,243 shares of the biotechnology company’s stock, valued at approximately $1,044,000.

Several other institutional investors also recently modified their holdings of BMRN. NewEdge Advisors LLC grew its stake in BioMarin Pharmaceutical by 11.5% in the 1st quarter. NewEdge Advisors LLC now owns 3,769 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 388 shares during the period. Empowered Funds LLC lifted its stake in shares of BioMarin Pharmaceutical by 207.4% during the 1st quarter. Empowered Funds LLC now owns 12,023 shares of the biotechnology company’s stock valued at $850,000 after buying an additional 8,112 shares in the last quarter. Focus Partners Wealth lifted its position in shares of BioMarin Pharmaceutical by 70.2% during the first quarter. Focus Partners Wealth now owns 11,817 shares of the biotechnology company’s stock worth $835,000 after acquiring an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC lifted its holdings in BioMarin Pharmaceutical by 33.0% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,439 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 1,102 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of BioMarin Pharmaceutical by 23.5% in the second quarter. Invesco Ltd. now owns 618,835 shares of the biotechnology company’s stock worth $34,017,000 after buying an additional 117,617 shares in the last quarter. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Stock Performance

Shares of BMRN opened at $66.64 on Tuesday. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The business’s 50 day moving average price is $59.76 and its 200-day moving average price is $57.58. BioMarin Pharmaceutical Inc. has a 52 week low of $49.26 and a 52 week high of $70.98. The stock has a market cap of $12.90 billion, a P/E ratio of 180.11, a P/E/G ratio of 0.47 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The firm had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. During the same period last year, the company earned $1.44 earnings per share. The company’s revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities research analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. UBS Group reiterated a “neutral” rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, July 14th. Weiss Ratings lowered shares of BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a report on Tuesday, August 11th. Sanford C. Bernstein dropped their target price on BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. HC Wainwright increased their price target on shares of BioMarin Pharmaceutical from $50.00 to $60.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Finally, Morgan Stanley increased their price objective on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $88.45.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.